Richard C. Duke
- Molecular Biology top 2%
- Immunology top 0.5%
- Oncology top 5%
- Epidemiology top 5%
- Cancer Research top 5%
- Co-authors
- John CohenKaren S. SellinsValerie A. FadokRobert ChervenakAlex FranzusoffDonald BellgrauJodene K. MooreHelena Selawry
- Topics
- Cell death mechanisms and regulation (10 papers)RNA Interference and Gene Delivery (9 papers)Immunotherapy and Immune Responses (9 papers)
- Partner nations
- United StatesAustraliaCanada
In The Last Decade
Richard C. Duke
51 papers receiving 6.3k citations
Hit Papers
Peers
Comparison fields: 5 of 136
- Molecular Biology 3.5k
- Immunology 2.5k
- Oncology 942
- Epidemiology 631
- Cancer Research 603
Countries citing papers authored by Richard C. Duke
This map shows the geographic impact of Richard C. Duke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard C. Duke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard C. Duke more than expected).
Fields of papers citing papers by Richard C. Duke
This network shows the impact of papers produced by Richard C. Duke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard C. Duke. The network helps show where Richard C. Duke may publish in the future.
Co-authorship network of co-authors of Richard C. Duke
This figure shows the co-authorship network connecting the top 25 collaborators of Richard C. Duke. A scholar is included among the top collaborators of Richard C. Duke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard C. Duke. Richard C. Duke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 33 | |
| 2 | Control of leukemia driven by T315I escape mutations in BCR-ABL with yeast-based Tarmogen immunotherapy | 2 |
| 3 | 3 | |
| 4 | 38 | |
| 5 | 2 | |
| 6 | 33 | |
| 7 | 73 | |
| 8 | 145 | |
| 9 | 51 | |
| 10 | 8 | |
| 11 | 9 | |
| 12 | 89 | |
| 13 | 68 | |
| 14 | 35 | |
| 15 | 16 | |
| 16 | 11 | |
| 17 | A role for CD95 ligand in preventing graft rejectionbreakdown → | 979 |
| 18 | 1 | |
| 19 | 132 | |
| 20 | 23 |
About Richard C. Duke
Richard C. Duke is a scholar working on Immunology, Biotechnology and Hepatology, having authored 51 papers that have together received 6.5k indexed citations. Recurring topics across this work include Cell death mechanisms and regulation (10 papers), RNA Interference and Gene Delivery (9 papers) and Immunotherapy and Immune Responses (9 papers). The work is most often cited by research in Immunology (2.5k citations), Molecular Biology (3.5k citations) and Cancer Research (603 citations). Richard C. Duke has collaborated with scholars based in United States, Australia and Canada. Frequent co-authors include John Cohen, Karen S. Sellins, Valerie A. Fadok, Robert Chervenak, Alex Franzusoff, Donald Bellgrau, Jodene K. Moore, Helena Selawry, Daniel P. Gold and John Ding‐E Young. Their work appears in journals such as Nature, Proceedings of the National Academy of Sciences and The Lancet.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.